ES2115691T3 - Derivados de benzotiepina, benzotiopirano y benzotiofeno, su obtencion y utilizacion de los mismos como farmacos. - Google Patents

Derivados de benzotiepina, benzotiopirano y benzotiofeno, su obtencion y utilizacion de los mismos como farmacos.

Info

Publication number
ES2115691T3
ES2115691T3 ES93106773T ES93106773T ES2115691T3 ES 2115691 T3 ES2115691 T3 ES 2115691T3 ES 93106773 T ES93106773 T ES 93106773T ES 93106773 T ES93106773 T ES 93106773T ES 2115691 T3 ES2115691 T3 ES 2115691T3
Authority
ES
Spain
Prior art keywords
benzotiopirano
benzotiofeno
benzotiepina
drugs
derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93106773T
Other languages
English (en)
Inventor
Michael Klaus
Peter Mohr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2115691T3 publication Critical patent/ES2115691T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/52—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes
    • C07D333/54—Benzo[b]thiophenes; Hydrogenated benzo[b]thiophenes with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D335/00—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
    • C07D335/04—Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D335/06—Benzothiopyrans; Hydrogenated benzothiopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D337/00—Heterocyclic compounds containing rings of more than six members having one sulfur atom as the only ring hetero atom
    • C07D337/02—Seven-membered rings
    • C07D337/06—Seven-membered rings condensed with carbocyclic rings or ring systems
    • C07D337/08—Seven-membered rings condensed with carbocyclic rings or ring systems condensed with one six-membered ring

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

COMPUESTOS DE FORMULA (I) Y SUS SALES DE ACIDOS CARBONICOS PUEDEN EMPLEARSE COMO MEDICAMENTO PARA EL TRATAMIENTO DE ENFERMEDADES AUTOIINMUNES O ENFERMEDADES CON COMPONENTES INMUNOLOGICOS FUERTES COMO PSORIASIS. SIENDO: R1, ALQUILO O ALCOXI DE C 7 A 10; R2 UN RESTO DE FORMULA (A) O (B); R3 CARBOXI O ALCOXICARBONILO DE BAJO NUMERO DE CARBONOS; X -S-, -SO-, O -SO2 1, 2 O 3.
ES93106773T 1992-05-07 1993-04-27 Derivados de benzotiepina, benzotiopirano y benzotiofeno, su obtencion y utilizacion de los mismos como farmacos. Expired - Lifetime ES2115691T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH146592 1992-05-07

Publications (1)

Publication Number Publication Date
ES2115691T3 true ES2115691T3 (es) 1998-07-01

Family

ID=4211112

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93106773T Expired - Lifetime ES2115691T3 (es) 1992-05-07 1993-04-27 Derivados de benzotiepina, benzotiopirano y benzotiofeno, su obtencion y utilizacion de los mismos como farmacos.

Country Status (13)

Country Link
US (2) US5391766A (es)
EP (1) EP0568898B1 (es)
JP (1) JP2549239B2 (es)
CN (1) CN1041417C (es)
AT (1) ATE164580T1 (es)
AU (1) AU666715B2 (es)
CA (1) CA2093577C (es)
DE (1) DE59308325D1 (es)
DK (1) DK0568898T3 (es)
ES (1) ES2115691T3 (es)
NZ (1) NZ247523A (es)
PH (1) PH30350A (es)
ZA (1) ZA933083B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7655699B1 (en) 1992-04-22 2010-02-02 Eisai Inc. Compounds having selective activity for retinoid X receptors, and means for modulation of processes mediated by retinoid X receptors
US5466861A (en) * 1992-11-25 1995-11-14 Sri International Bridged bicyclic aromatic compounds and their use in modulating gene expression of retinoid receptors
US5475022A (en) * 1993-10-18 1995-12-12 Allergan, Inc. Phenyl or heteroaryl and tetrahydronaphthyl substituted diene compounds having retinoid like biological activity
US6107494A (en) * 1994-09-13 2000-08-22 G.D. Searle And Company Substituted 5-aryl-benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6268392B1 (en) 1994-09-13 2001-07-31 G. D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothiepines and HMG Co-A reductase inhibitors
US5994391A (en) * 1994-09-13 1999-11-30 G.D. Searle And Company Benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US6642268B2 (en) 1994-09-13 2003-11-04 G.D. Searle & Co. Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors
US6262277B1 (en) 1994-09-13 2001-07-17 G.D. Searle And Company Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake
US5977125A (en) * 1994-10-31 1999-11-02 Eisai Co., Ltd. Mono-or polyenic carboxylic acid derivatives
US5534261A (en) * 1995-01-17 1996-07-09 University Of Southern California Retinoid-based compositions and method for preventing adhesion formation using the same
US7115728B1 (en) * 1995-01-30 2006-10-03 Ligand Pharmaceutical Incorporated Human peroxisome proliferator activated receptor γ
US5807900A (en) * 1995-03-31 1998-09-15 Hoffmann-La Roche, Inc. Method for identifying compounds having increased activity for the repair of skin photodamage
US5675033A (en) * 1995-06-06 1997-10-07 Allergan 2,4-pentadienoic acid derivatives having retinoid-like biological activity
JP3964478B2 (ja) * 1995-06-30 2007-08-22 エーザイ・アール・アンド・ディー・マネジメント株式会社 ヘテロ環含有カルボン酸誘導体及びそれを含有する医薬
CA2233888A1 (en) 1995-10-06 1997-04-10 Ligand Pharmaceuticals Incorporated Dimer-selective rxr modulators and methods for their use
FR2746098B1 (fr) * 1996-03-14 1998-04-30 Composes propynyl biaromatiques
FR2752837B1 (fr) * 1996-09-02 1999-11-12 Cird Galderma Nouveaux composes modulateurs des recepteurs hormonaux, les compositions les comprenant et leur utilisation en therapie
FR2753627B1 (fr) * 1996-09-20 2003-02-21 Galderma Rech Dermatologique Utilisation des inhibiteurs de l'activite de l'acide retinoique pour favoriser la cicatrisation
FR2755011B1 (fr) * 1996-10-31 1998-11-20 Cird Galderma Utilisation des inhibiteurs de l'activite de l'acide retinoique pour traiter les peaux sensibles et/ou les dommages aigus induits par les rayonnements u.v.
FR2756561B1 (fr) * 1996-12-04 1999-01-08 Cird Galderma Composes heteroaryles, compositions pharmaceutiques et cosmetiques les contenant et utilisations
US7098025B1 (en) 1997-07-25 2006-08-29 Ligand Pharmaceuticals Incorporated Human peroxisome proliferator activated receptor gamma (pparγ) gene regulatory sequences and uses therefor
EP0908179A1 (en) 1997-08-23 1999-04-14 Werner Bollag Treatment of cell-mediated immune diseases
US8541469B2 (en) * 1997-08-23 2013-09-24 Glaxo Group Limited Treatment of cell-mediated immune diseases
KR100440836B1 (ko) * 1997-11-12 2004-07-19 에프. 호프만-라 로슈 아게 레티노이드 길항제를 이용한 제2형 ｔ-보조세포 중재 면역질환의 치료
US6083973A (en) * 1998-03-09 2000-07-04 Syntex (U.S.A.) Inc. Methods for inhibiting mucin secretion using RAR α selective antagonists
US6326397B1 (en) 1998-11-10 2001-12-04 Hoffman-La Roche Inc. Retinoid antagonists and use thereof
EP1340510A1 (en) 1998-12-23 2003-09-03 G.D. Searle LLC. Combinations of cholesteryl ester transfer protein inhibitors and bile acid sequestering agents for cardiovascular indications
PL348508A1 (en) 1998-12-23 2002-05-20 Searle Llc Combinations of ileal bile acid transport inhibitors and cholesteryl ester transfer protein inhibitors for cardiovascular indications
CN1342090A (zh) 1998-12-23 2002-03-27 G·D·瑟尔有限公司 适用于心血管疾病的回肠胆汁酸转运抑制剂和贝酸衍生物的组合
AU2157400A (en) 1998-12-23 2000-07-31 G.D. Searle & Co. Combinations of cholesteryl ester transfer protein inhibitors and hmg coa reductase inhibitors for cardiovascular indications
JP2002533414A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するための回腸胆汁酸輸送阻害剤および胆汁酸隔離剤の組み合わせ
JP2002533410A (ja) 1998-12-23 2002-10-08 ジー．ディー．サール エルエルシー 心臓血管に適用するためのコレステリルエステル転送タンパク質阻害剤およびフィブリン酸誘導体の組み合わせ
US6489366B1 (en) 1998-12-23 2002-12-03 G. D. Searle, Llc Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications
EP1212322A2 (en) 1999-08-27 2002-06-12 Ligand Pharmaceuticals Incorporated 8-substituted-6-trifluoromethyl-9-pyrido[3,2-g]quinoline compounds as androgen receptor modulators
TR200200507T2 (tr) 1999-08-27 2002-10-21 Ligand Pharmaceuticals Inc Androjen reseptörü modülatör bileşikleri ve metotları
US6566372B1 (en) 1999-08-27 2003-05-20 Ligand Pharmaceuticals Incorporated Bicyclic androgen and progesterone receptor modulator compounds and methods
AU7586600A (en) * 1999-09-14 2001-04-17 Ligand Pharmaceuticals Incorporated Rxr modulators with improved pharmacologic profile
WO2001068637A2 (en) 2000-03-10 2001-09-20 Pharmacia Corporation Method for the preparation of tetrahydrobenzothiepines
MXPA04003524A (es) 2001-11-02 2004-07-23 Searle Llc Compuestos de benzotiepina monofluorados y difluorados novedosos como inhibidores de transporte de acido biliar co-dependiente de sodio apical (asbt) y captacion de taurocolato.
BR0306643A (pt) 2002-01-17 2004-10-19 Pharmacia Corp Novos compostos de hidroxi alquil/aril ou ceto tiepina como inibidores do transporte co-dependente de ácido biliar-sódio apical
JP2004020220A (ja) * 2002-06-12 2004-01-22 Pioneer Electronic Corp 通信システム及び方法、通信端末装置、通信センタ装置、並びにコンピュータプログラム
US20060151574A1 (en) * 2002-11-29 2006-07-13 Gpc Biotech Ag Formulations useful against hepatitis C virus infections
EP1527774A1 (en) 2003-11-03 2005-05-04 Basilea Pharmaceutica AG New formulation for retinoid-containing soft gelatin capsules
CA2569738A1 (en) * 2004-06-07 2005-12-22 Duramed Pharmaceuticals, Inc. Dispenser for progestin used for acute and maintenance treatment of dub

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH651034A5 (de) * 1982-05-12 1985-08-30 Hoffmann La Roche Chroman-, thiochroman- oder 1,2,3,4-tetrahydrochinolinderivate und ihre verwendung als arzneimittel-wirkstoffe.
WO1985000806A1 (en) * 1983-08-08 1985-02-28 Sri International Benzonorbornenyl, benzopyranyl and benzothiopyranyl retinoic acid analogues
US4810804A (en) * 1987-03-26 1989-03-07 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a heterobicyclic group having retinoid-like activity
US4833254A (en) * 1987-05-11 1989-05-23 The Board Of Regents For The Oklahoma Agricultural And Mechanical Colleges Acting For And On Behalf Of Oklahoma State University Heteroarotinoids as anticancer agents
GB8800397D0 (en) * 1988-01-08 1988-02-10 Sandoz Ltd Improvements in/relating to organic compounds
AU626881B2 (en) * 1988-07-14 1992-08-13 F. Hoffmann-La Roche Ag Benzofused heterocyclics used as pharmaceuticals
US4980369A (en) * 1989-09-19 1990-12-25 Allergan, Inc. Acetylenes disubstituted with a phenyl group and a 2-substituted chromanyl or thiochromanyl group having retinoid-like activity

Also Published As

Publication number Publication date
NZ247523A (en) 1995-06-27
AU666715B2 (en) 1996-02-22
AU3710893A (en) 1993-11-11
JPH069616A (ja) 1994-01-18
US5391766A (en) 1995-02-21
CA2093577C (en) 2006-01-03
EP0568898B1 (de) 1998-04-01
PH30350A (en) 1997-04-02
CA2093577A1 (en) 1993-11-08
ATE164580T1 (de) 1998-04-15
CN1041417C (zh) 1998-12-30
DE59308325D1 (de) 1998-05-07
US5512683A (en) 1996-04-30
JP2549239B2 (ja) 1996-10-30
ZA933083B (en) 1994-09-26
DK0568898T3 (da) 1999-01-18
CN1080922A (zh) 1994-01-19
EP0568898A1 (de) 1993-11-10

Similar Documents

Publication Publication Date Title
ES2115691T3 (es) Derivados de benzotiepina, benzotiopirano y benzotiofeno, su obtencion y utilizacion de los mismos como farmacos.
FI935555A0 (fi) Nya sulfonamider
ATE170837T1 (de) Indolderivate
FI935360A0 (fi) Guanidinalkyl-1,1-bifosfonsyraderivat, foerfarande foer deras framstaellning samt deras anvaendning
MX9201760A (es) Quinoxalinas, procedimiento para su preparacion y su empleo.
ATE157088T1 (de) Neue chinolon- und naphthyridoncarbonsäurederivate
FI922095A7 (fi) Substitioituja karboksyylihappojohdannaisia
NO943232L (no) Aromatiske karboksylsyrederivater
FI102964B1 (fi) Terapeuttisia yhdisteitä
NO923508D0 (no) Bicykliske karboksylsyrederivater
DE3688721D1 (de) Verwendung von porphyrinderivaten bei der entdeckung und behandlung von tumoren.
NO923200D0 (no) Piperidin-derivater
NO912545D0 (no) Nye 3,3'-ditobis (propionsyrer) og estere derav samt fremgangsmaate for dens fremstilling.
ATE63684T1 (de) Deodorant.
HU9400908D0 (en) Pharmaceutical compositions for treatng skin disorders
NO171912C (no) Fremgangsmaate for fremstilling av 5-klor-3-klorsulfonyl-2-tiofenkarboksylsyreestere
ATE86974T1 (de) (2-cyan-2-oximinoacetyl)-aminosaeure-derivate.
ATE87906T1 (de) (2-cyan-2-oximinoacetyl)-aminosaeure-derivate.
TW258733B (es)
NO166788C (no) Fremgangsmaate for fremstilling av terapeutisk aktive tetrahydrobenzofuro(2,3-c)-pyridiner.
ES2080445T3 (es) Derivados de ursano, su preparacion y formulaciones farmaceuticas de los mismos.
ZA845517B (en) 2-(formylamino)-n-(1h-tetrazol-5-yl)benzamide
MA22839A1 (fr) Procede de preparation d'esters de 2-amino-7-(1,3-dihydroxy-2-propoxymethyl) purine avec des acides carboxyliques.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 568898

Country of ref document: ES